# OnCo record mrdx-bcr-abl (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mrdx-bcr-abl/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "mrdx-bcr-abl" ;
  schema:name "MRDx BCR-ABL Test"@en ;
  schema:description "An FDA-cleared blood test that measures the BCR-ABL1 signal of chronic myeloid leukaemia, listed by the FDA as a companion to nilotinib."@en ;
  schema:url <https://onco.cc/drugs/mrdx-bcr-abl/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K173492>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>, <https://www.iconplc.com/news-events/press-releases/icon-acquires-molecularmd> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "BCR-ABL1 monitoring test (blood)" ;
  schema:alternateName "MRDx BCR-ABL Test" ;
  onco:approval "US 2017: 510(k) clearance; companion to nilotinib in chronic myeloid leukaemia (peripheral blood)" ;
  onco:related <https://onco.cc/biomarkers/bcr-abl1-transcript/> ;
  onco:cancers <https://onco.cc/cancers/cml/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:drugs <https://onco.cc/drugs/nilotinib/> ;
  onco:companies <https://onco.cc/companies/molecularmd/> ;
  onco:terms <https://onco.cc/terms/companion-diagnostic-term/> .